Screener
Amphastar Pharmaceuticals AMPH Finished Pharmaceutical Products — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Amphastar Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:50 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001297184-26-000047
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| BAQSIMI® | $45,503 | $46,687 | $77,937 | $85,042 |
| Primatene MIST® | 21,004 | 22,880 | 50,767 | 51,931 |
| Epinephrine | 15,854 | 16,180 | 35,067 | 34,767 |
| Lidocaine | 15,039 | 14,999 | 28,499 | 28,643 |
| Glucagon | 11,905 | 20,602 | 21,075 | 41,445 |
| Ipratropium bromide | 8,411 | — | 8,411 | — |
| Other products | 66,187 | 53,066 | 133,318 | 103,114 |
| Total net revenues | $183,903 | $174,414 | $355,074 | $344,942 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Amphastar Pharmaceuticals's finished pharmaceutical products — revenue?
- Amphastar Pharmaceuticals (AMPH) reported finished pharmaceutical products — revenue of $183.9M in Q2 2026.
- How has Amphastar Pharmaceuticals's finished pharmaceutical products — revenue changed year-over-year?
- Amphastar Pharmaceuticals's finished pharmaceutical products — revenue increased by 5.4% year-over-year, from $174.41M to $183.9M.
- What is the long-term trend for Amphastar Pharmaceuticals's finished pharmaceutical products — revenue?
- Over 2 years (2021 to 2023), Amphastar Pharmaceuticals's finished pharmaceutical products — revenue has grown at a 22.6% compound annual growth rate (CAGR), from $419.57M to $630.27M.
- What does finished pharmaceutical products — revenue mean?
- This metric represents the total net sales generated from the sale of finished injectable, inhalation, and intranasal pharmaceutical products within the specified business segment. It serves as a primary indicator of market demand and the commercial success of the company's core product portfolio in hospital and clinical settings.
Ask your AI about Amphastar Pharmaceuticals's finished pharmaceutical products — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude